Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company is dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. The Company receives royalty revenues on seven marketed products that utilize its Customized PEGylation Linker Technology (Customized Linker Technology) platform, namely PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. PEGINTRON is a PEG-enhanced version of Merck�s alpha interferon product, INTRON A, which is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Sylatron is approved for the adjuvant treatment of melanoma. Macugen (pegaptanib sodium injection) is being marketed by Valeant and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.